Connection
Search Results to
This is a "connection" page, showing the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
| Property | Value |
|
has major subject area list
|
Antineoplastic Agents; bcl-X Protein; Deoxycytidine; Drug Resistance, Neoplasm; Pancreatic Neoplasms; Piperazines
|
|
information resource reference
|
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther. 2022 01; 21(1):184-192.
|
|
label
|
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
|